Paul Matteis
Stock Analyst at Stifel
(2.99)
# 1,362
Out of 5,113 analysts
125
Total ratings
45.24%
Success rate
0.6%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Buy | $50 → $40 | $25.27 | +58.29% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $134.51 | +39.77% | 11 | Dec 11, 2025 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $27 → $35 | $22.38 | +56.39% | 2 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $18.00 | +116.67% | 5 | Dec 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $495 → $508 | $361.35 | +40.58% | 16 | Dec 11, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $24 → $25 | $26.86 | -6.92% | 6 | Dec 11, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $28 | $17.98 | +55.73% | 1 | Nov 21, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Hold | $2 → $3 | $2.04 | +47.06% | 3 | Nov 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Hold | $73 → $61 | $56.78 | +7.43% | 11 | Nov 6, 2025 | |
| BIIB Biogen | Upgrades: Buy | $144 → $202 | $173.12 | +16.69% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $455 → $445 | $476.84 | -6.68% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $43 → $67 | $81.00 | -17.28% | 6 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $5.31 | +125.99% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $103.39 | -9.08% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $42.60 | -24.88% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $16.60 | +92.77% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $6.90 | +59.42% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.93 | +107.25% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $16.41 | -39.06% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $19.12 | +213.81% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $33.11 | +8.73% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.45 | +32.33% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $12.99 | +123.25% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.51 | +166.31% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.62 | +1,822.15% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $14.91 | +114.62% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.08 | +1,198.08% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $21.57 | -35.10% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $13.25 | +383.02% | 1 | Feb 21, 2018 |
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $25.27
Upside: +58.29%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $134.51
Upside: +39.77%
LB Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $27 → $35
Current: $22.38
Upside: +56.39%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $18.00
Upside: +116.67%
Alnylam Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $361.35
Upside: +40.58%
ACADIA Pharmaceuticals
Dec 11, 2025
Maintains: Hold
Price Target: $24 → $25
Current: $26.86
Upside: -6.92%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $17.98
Upside: +55.73%
Neumora Therapeutics
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $2.04
Upside: +47.06%
BioMarin Pharmaceutical
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $56.78
Upside: +7.43%
Biogen
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $173.12
Upside: +16.69%
Nov 4, 2025
Maintains: Hold
Price Target: $455 → $445
Current: $476.84
Upside: -6.68%
Oct 6, 2025
Maintains: Hold
Price Target: $43 → $67
Current: $81.00
Upside: -17.28%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $5.31
Upside: +125.99%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $103.39
Upside: -9.08%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $42.60
Upside: -24.88%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $16.60
Upside: +92.77%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $6.90
Upside: +59.42%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.93
Upside: +107.25%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $16.41
Upside: -39.06%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $19.12
Upside: +213.81%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $33.11
Upside: +8.73%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $26.45
Upside: +32.33%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $12.99
Upside: +123.25%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $7.51
Upside: +166.31%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.62
Upside: +1,822.15%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $14.91
Upside: +114.62%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.08
Upside: +1,198.08%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $21.57
Upside: -35.10%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $13.25
Upside: +383.02%